News
Research and Markets: Recordati Company Intelligence Reports Provide a Full Review of the Company's Activities Together with Five Year Sales Forecasts
DUBLIN, Ireland-(Business Wire)-August 3, 2007 - Research and Markets (http://www.researchandmarkets.com/reports/c64734) has announced the addition of "Recordati: Performance, Products, Pipeline and Potential" to their offering.
Pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.
Recordati markets products in the following fields: Cardiovascular, Central Nervous System, Gastroenterology/Urology; Respiratory and Anti-infectives. The company is active in the following areas of research: Cardiovascular; Central Nervous System, Gastroenterology/Urology and Anti-infectives. However, future research efforts will focus on fixed combinations in the treatment of hypertension and the development of therapies for micturition disorders.
Europe is increasingly becoming Recordati's market of reference and the German and British transactions which were concluded in 2005 (namely the acquisitions of Merckle Recordati and Recordati Pharmaceuticals) therefore represent two fundamental steps in Recordati's strategy allowing the company to gain access to two key European markets. Recordati plans selective acquisitions in countries where it already has a presence, including Germany, Spain and the UK. Recordati also has expansion plans in Eastern Europe, which it believes have very interesting development prospects. Due to these operations and to the establishment of subsidiaries in Portugal and Greece, Recordati now covers 80 per cent of the European pharmaceutical market with an overall field force of over 1,000 medical representatives.
Recordati believes its extended European coverage, consolidated expertise in concluding effective collaborations with third parties and its competence and experience in dealing with European regulatory affairs authorities, make the company competitive in obtaining new product licenses for the European markets, even against the larger pharmaceutical companies. Recordati is also making efforts to maximise the potential of its in-house developed products.
Recordati has worked to nurture a pipeline containing a variety of novel candidate drugs in a range of therapeutic areas, largely through in-licensing. As a company operating on a small scale, Recordati has needed to adopt this strategy in order to create a competitive pipeline, however, the sales growth of Recordati's major products in recent years has meant the company can continue to increase its investment in R&D year-on-year. In 2006, Recordati's products experienced a mixed year as certain products were badly hit by changes to reimbursement and pricing schemes in several European markets. Other, newer products continued to perform well with some strong launches. Furthermore, the construction of a new R&D facility at the Ringaskiddy site (Cork, Ireland) began in 2005, and this could see Recordati begin to produce a greater amount of in-house projects in areas of particular focus.
This new strategic analysis report Recordati: Performance, Products, Pipeline and Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. The report is updated on a quarterly basis. Buyers of the web edition receive quarterly reports for a year. Buyers of the print/pdf editions receive the latest version. All formats are the same price. -0- *T Contents: EXECUTIVE SUMMARY A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis. THERAPEUTIC AREA FOCUS Key product analysis and forecasting Cardiovascular Zanidip/Zanedip (lercanidipine) Central Nervous System Elopram/Entact (citalopram/escitalopram) Tora-dol (ketorolac trometamol) Tradorec XL (tramadol) Gastroenterology/Urology Peptazol/Ulcotenal (pantoprazole) Respiratory Exomuc and Hexa (acetylcysteine and biclotimol) Anti-Infectives Isocef (ceftibuten) Octegra (moxifloxacin) OPERATIONAL DATA A wealth of background and detail A full 5-year financial performance assessment Key corporate events Key agreements Infrastructure Subsidiaries *T
For more information visit http://www.researchandmarkets.com/reports/c64734
Source: Espicom
